Previous research has shown that irradiated splenocytes preserve the antitumor effect and induce relatively weaker graft-versus-host disease in parent C57BL/6SCB6F1 transplantation. The present study was designed to investigate the antitumor effect of 5-Gy-irradiated haploidentical donor leukocyte infusions (DLI) without prior bone marrow transplantation and the possibly involved mechanism in (H-2d/k)→(H-2b/d) infusion model systems.
Methods
Hepa 1–6 tumor-bearing mice were used to evaluate the antitumor effect and the possible mechanism of irradiated haploidentical DLI treatment. Changes in tumor volume, lymphocyte proliferation and cytotoxicity, IFN-gamma and IL-2 secretion and donor cell survival in vivo were analyzed.
Results
After irradiated haploidentical DLI treatment of the poorly immunogeneic Hepa 1–6 tumor mouse model, the donor cells were rejected and disappeared within 4 days. Surprisingly, an antitumor response was still observed. The infusion treatment effectively inhibited tumor growth and prolonged the survival of recipients, and this effect could be enhanced by combined treatment with cyclophosphamide and impaired by deleting donor-derived T cells. Moreover, the infusion treatment increased the levels of type 1 cytokines including IFN-gamma and IL-2, and enhanced the proliferation of lymphocyte subsets, particularly CD8+ T and NK cells. Specifically, multiple infusions proved to enhance the antitumor effect without inducing graft-versus-host disease.
Conclusions
As an adoptive therapy, irradiated haploidentical DLI without bone marrow transplantation might be a promising and safe treatment for cancer.
KolbH.J., MittermüllerJ., ClemmC., HollerE., LedderoseG., BrehmG., HeimM., WilmannsW.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.Blood, 76: 2462–2465, 1990.
2.
LokhorstH.M., WuK., VerdonckL.F., LaterveerL.L., van de DonkN.W., van OersM.H., CornelissenJ.J., SchattenbergA.V.: The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma.Blood, 103: 4362–4364, 2004.
3.
PorterD.L., ConnorsJ.M., Van DeerlinV.M., DuffyK.M., McGarigleC., SaidmanS.L., LeonardD.G., AntinJ.H.: Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies.J Clin Oncol, 17: 1234–1243, 1999.
4.
IgietsemeJ.U., SmithK., SimmonsA., RayfordP.L.: Effect of gamma-irradiation on the effector function of T lymphocytes in microbial control.Int J Radiat Biol, 67: 557–564, 1995.
5.
LuP.H., NegrinR.S.: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.J Immunol, 153: 1687–1696, 1994.
6.
MuraokaS., MillerR.G.: Cells in murine fetal liver and in lymphoid colonies grown from fetal liver can suppress generation of cytotoxic T lymphocytes directed against their self antigens.J Immunol, 131: 45–49, 1983.
7.
WallerE.K., BoyerM.: New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.Bone Marrow Transplant, 25(Suppl 2): S20–24, 2000.
8.
WallerE.K., ShipA.M., MittelstaedtS., MurrayT.W., CarterR., KakhniashviliI., LonialS., HoldenJ.T., BoyerM.W.: Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.Blood, 94: 3222–3233, 1999.
ChenQ., LinR.B., YeY.B., FanN.F., GuoZ.Q., ZhouZ.F., WangX.J., ChenM.S., ChenS.P., LiJ.Y.: The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report.Med Oncol, 27: 554–558, 2010.
11.
LiX.F., ChenQ., YeY.B., FanL.F., ChenM.S., LiJ.Y., ChenH.Q., ChenS.P., ZhouZ.F.: Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response.Zhongguo Shi Yan XueYe Xue Za Zhi, 15: 160–164, 2007.
12.
SlavinS., NaparstekE., NaglerA., AckersteinA., KapelushnikJ., OrR.: Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.Exp Hematol, 23: 1553–1562, 1995.
13.
SlavinS., NaparstekE., NaglerA., AckersteinA., SamuelS., KapelushnikJ., BrautbarC., OrR.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.Blood, 87: 2195–2204, 1996.
14.
SuX., GuoS., ZhouC., WangD., MaW., ZhangS.: A simple and effective method for cancer immunotherapy by inactivated allogeneic leukocytes infusion.Int J Cancer, 124: 1142–1151, 2009.
LuznikL., FuchsE.J.: Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.Cancer Control, 9: 123–137, 2002.
17.
YuJ., TianR., XiuB., YanJ., JiaR., ZhangL., ChangA.E., SongH., LiQ.: Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.Int J Biol Sci, 5: 135–146, 2009.
18.
RosenbergS.A., DudleyM.E.: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.Proc Natl Acad Sci USA, 101(Suppl 2): 14639–14645, 2004.
19.
MillerJ.S., SoignierY., Panoskaltsis-MortariA., McNearneyS.A., YunG.H., FautschS.K., McKennaD., LeC., DeforT.E., BurnsL.J., OrchardP.J., BlazarB.R., WagnerJ.E., SlungaardA., WeisdorfD.J., OkazakiI.J., McGlaveP.B.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.Blood, 105: 3051–3057, 2005.
20.
IkedaH., ChamotoK., TsujiT., SuzukiY., WakitaD., TakeshimaT., NishimuraT.: The critical role of type-1 innate and acquired immunity in tumor immunotherapy.Cancer Sci, 95: 697–703, 2004.
RubioM.T., KimY.M., SachsT., MaparaM., ZhaoG., SykesM.: Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma.Blood, 102: 2300–2307, 2003.
23.
LuY., WallerE.K.: Dichotomous role of interferon-gamma in allogeneic bone marrow transplant.Biol Blood Marrow Transplant, 15: 1347–1353, 2009.
24.
SaitoT.I., LiH.W., SykesM.: Invariant NKT cells are required for antitumor responses induced by host-versus-graft responses.J Immunol, 185: 2099–2105, 2010.
25.
BracciL., MoschellaF., SestiliP., La SorsaV., ValentiniM., CaniniI., BaccariniS., MaccariS., RamoniC., BelardelliF., ProiettiE.: Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.Clin Cancer Res, 13: 644–653, 2007.
26.
LiuJ.Y., WuY., ZhangX.S., YangJ.L., LiH.L., MaoY.Q., WangY., ChengX., LiY.Q., XiaJ.C., MasucciM., ZengY.X.: Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.Cancer Immunol Immunother, 56: 1597–1604, 2007.
27.
ProiettiE., GrecoG., GarroneB., BaccariniS., MauriC., VendittiM., CarleiD., BelardelliF.: Importance of cyclophosphamide-induced by stander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.J Clin Invest, 101: 429–441, 1998.
